Clinical trials: Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM)
A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
Primary objective: Glycemic control after initiation or switch to insulin glargine 300 U/ml in everyday clinical practice Secondary objective: Treatment satisfaction
- Trial name
- ELDERLY-T (NCT05607160)
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers
This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 and to investigate the effect of food on the pharmacokinetics of DA-1229_01 in healthy male volunteers
- Trial name
- NCT02167061
- Testing
- DA-1229_01, E+M, DA-1229_01 fast
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Type 1 Diabetes
Investigation of Hyposafe H02 Device in Patients With Type 1 Diabetes
This clinical study is designed to collect data for further development of a hypoglycaemia notification algorithm. In addition, information regarding safety will be collected and analysed.
- Trial name
- NCT05495386
- Testing
- Hyposafe hypoglycaemia notification device (H02)
- Sponsor
- UNEEG Medical A/S
Diabetes
Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System
The Quo-Test A1C Analyzer and Reagent Test System (Quo-Test A1C System) are intended for the in-vitro quantitative determination of glycated hemoglobin in whole blood samples obtained from fingerstick or venous samples for…
- Trial name
- NCT01829061
- Where
- 3 sites in United States
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Quotient Diagnostics Limited
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus
the pharmacokinetics, pharmacodynamics and safety and tolerability of single and multiple oral doses of BI 10773 at low dose once daily (q.d.) and high dose q.d.
- Trial name
- NCT01316341
- Testing
- BI10773
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes Mellitus
A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)
The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1 diabetes.
- Trial name
- NCT01686620
- Testing
- BIOD-123, Lispro (Humalog)
- Where
- 34 sites in United States
- Volunteers
- 132 people
- Sponsor
- Biodel
Type 2 Diabetes Mellitus
A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02419859
- Testing
- PaQ® Insulin Delivery Device, Insulin, Asp(B28)-
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- CeQur Corporation
Hypercholesterolemia, Atherosclerosis
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20…
- Conditions
- Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT00651378
- Testing
- Rosuvastatin, Ezetimibe + Atorvastatin, Double Atorvastatin
- Volunteers
- 87 people
- Sponsor
- Organon and Co
Type 1 Diabetes Mellitus
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)
The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes.
- Trial name
- NCT03743285
- Testing
- AID System, Insulin Lispro
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus
The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia.
- Trial name
- SAMS12 (NCT00495885)
- Testing
- volinanserin (M100907)
- Where
- 16 sites in United States, Brazil and 14 more
- Volunteers
- 848 people
- Sponsor
- Sanofi
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Obesity, Type 2 Diabetes
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adult subjects with type 2 diabetes mellitus.
- Trial name
- NCT02324491
- Testing
- ZGN-440 for Injectable Suspension
- Where
- 16 sites in Australia
- Volunteers
- 152 people
- Sponsor
- Zafgen, Inc.
Vitreous Hemorrhage, Diabetic Retinopathy
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
- Trial name
- NCT00198510
- Testing
- Vitrase
- Where
- 73 sites in United States, Canada and 1 more
- Volunteers
- 750 people
- Sponsor
- Bausch & Lomb Incorporated
Metabolic Disorders, Non-alcoholic Steatohepatitis
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in…
- Trial name
- NCT04142424
- Testing
- AZD2693
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity, Obesity, Abdominal
Vestibular Stimulation to Trigger Adipose Loss Clinical Trial
There is an ongoing and worsening problem with obesity in the developed, and much of the developing world. Although it has long been realized that Western diets that are rich in sugar and fat play an important role in this, it…
- Conditions
- Obesity, Obesity, Abdominal, Metabolic Syndrome, Weight Loss
- Trial name
- VeSTAL (NCT03138369)
- Testing
- Vestibular nerve stimulator
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Neurovalens Ltd.
Diabetes Mellitus, Type 2
First Time in Human Study Using GSK2330672
The purpose of this study is to look at the safety and tolerability of increasing single doses of GSK2330672 in healthy volunteers.
- Trial name
- NCT01416324
- Testing
- 0.1 mg GSK2330672, 0.3 mg GSK2330672, 1 mg GSK2330672
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitus
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients…
- Trial name
- NCT00920582
- Testing
- Teplizumab Herold Regimen, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen
- Where
- 118 sites in United States, Belgium and 14 more
- Volunteers
- 254 people
- Sponsor
- MacroGenics
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to evaluate the blood glucose-lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in subjects with type 2 diabetes.
- Trial name
- NCT01134224
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.